MARKET

CRIS

CRIS

Curis
NASDAQ
1.020
+0.051
+5.30%
Opening 13:41 02/10 EST
OPEN
0.9900
PREV CLOSE
0.9688
HIGH
1.050
LOW
0.9645
VOLUME
155.66K
TURNOVER
--
52 WEEK HIGH
3.409
52 WEEK LOW
0.7710
MARKET CAP
13.19M
P/E (TTM)
-0.2775
1D
5D
1M
3M
1Y
5Y
1D
Curis Regains Nasdaq Compliance, Remains Under Monitoring Period
TipRanks · 20h ago
Curis Inc. gibt Termin für Sonderaktionärstreffen bekannt
Reuters · 20h ago
Curis Inc. Announces Date for Upcoming Special Meeting of Stockholders
Reuters · 20h ago
Curis Faces Nasdaq Delisting Risk After Compliance Monitoring Notice
Reuters · 20h ago
Weekly Report: what happened at CRIS last week (0202-0206)?
Weekly Report · 1d ago
Weekly Report: what happened at CRIS last week (0126-0130)?
Weekly Report · 02/02 09:53
Weekly Report: what happened at CRIS last week (0119-0123)?
Weekly Report · 01/26 09:54
Weekly Report: what happened at CRIS last week (0112-0116)?
Weekly Report · 01/19 09:58
More
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.

Webull offers Curis Inc stock information, including NASDAQ: CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.